Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell...

Full description

Bibliographic Details
Main Authors: Baker, Amanda F., Hanke, Neale T., Sands, Barbara J., Carbajal, Liliana, Anderl, Janet L., Garland, Linda L.
Other Authors: University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology
Language:en
Published: BioMed Central 2014
Subjects:
Carfilzomib
Proteasome inhibitor
Lung cancer
Cisplatin
Online Access:http://hdl.handle.net/10150/610318
http://arizona.openrepository.com/arizona/handle/10150/610318

Internet

http://hdl.handle.net/10150/610318
http://arizona.openrepository.com/arizona/handle/10150/610318

Similar Items